Cultural Adaptation, Validity, and Reliability of the Turkish Version of North Star Ambulatory Assessment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Güllü Aydın Yağcıoğlu, PhD
- Phone Number: 05536140823
- Email: gulluaydin23@gmail.com
Study Locations
-
-
-
Isparta, Turkey, 32100
- Güllü Aydın Yağcıoğlu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being diagnosed with DMD
- Ambulatory
- Being between the ages of 4-18
- Agreeing to participate in the research voluntarily
Exclusion Criteria:
- Insufficient cooperation with the physiotherapist,
- Have had any injury and/or surgery of the lower extremities in the last 6 months,
- Having neurological problems in addition to DMD. -
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
North Star Ambulatory Assessment
Time Frame: 10 minutes
|
The North Star Ambulatory Assessment (NSAA) is a functional scale specifically designed for ambulant boys with DMD.
The instrument contains clear and detailed instructions, with item scores varying according to a simple three point criteria, which should allow accurate reproduction by different groups.
The scale has also the advantage to be quick to perform and to be suitable for application in young children.
The NSAA also includes two timed items, run/walk for 10 meters and rise from the floor.
While those times do not influence the score, they can be used to monitor changes over time.
Although it was developed to assess ambulatory patients, the NSAA has been widely accepted and used to evaluate ambulatory motor performance in children and young adults with DMD, as well as in patients with other neuromuscular diseases.
|
10 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motor Function Measure (MFM)
Time Frame: 20-30 minutes
|
MFM, which was valid and reliable in Neuromuscular Diseases, was used for gross motor function assessment.
The items in MFM, which evaluate functions in 3 different sections (D1, standing position and transfers; D2, axial and proximal motor function; D3, distal motor function) in 32 items in total, are scored between 0-3.
0; cannot initiate any movement and maintain the starting position, 1; partially completes the exercise, 2; performs the exercise slowly and visibly clumsily, with compensations, 3; performs the exercise in the specified standard pattern.
High scores indicate higher motor function and the result is expressed as a percentage of the maximum possible score to enable comparison with other scores
|
20-30 minutes
|
|
6 meter walking test (6MWT)
Time Frame: 6 minutes
|
6MWT is an assessment that was developed by Balke in the 1960s and has validity and reliability for DMD patients.
The maximum distance that the patient can walk in 6 minutes is recorded as meters.
|
6 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Güllü Aydın Yağcıoğlu, PhD, Hacettepe University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NSAA-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.